Literature DB >> 19729047

Regulation of vitamin D receptor function in MEN1-related parathyroid adenomas.

Koen M A Dreijerink1, Radhika A Varier, Rick van Nuland, Roel Broekhuizen, Gerlof D Valk, Jacqueline E van der Wal, Cornelis J M Lips, J Alain Kummer, H Th Marc Timmers.   

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is a heriditary syndrome characterised by the occurrence of parathyroid, gastroenteropancreatic and pituitary tumours. The MEN1 gene product, menin, co-activates gene transcription by recruiting histone methyltransferases for lysine 4 of histone H3 (H3K4). We investigated whether in MEN1 tumours global changes in H3K4 trimethylation (H3K4me3) occur or whether alterations in gene expression can be observed. By immunohistochemistry we found that global levels of H3K4me3 are not affected in MEN1-related parathyroid adenomas. Menin can interact directly with the vitamin D receptor (VDR) and enhance the transcriptional activity of VDR. Messenger RNA levels of VDR target genes CYP24 and KLK6 were significantly lower in MEN1 parathyroid adenomas compared to normal tissue. Thus, aberrant gene expression in MEN1 tumours is not caused by lower global H3K4me3, but rather by specific effects on genes that are regulated by menin-interacting proteins, such as VDR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729047     DOI: 10.1016/j.mce.2009.08.020

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  17 in total

Review 1.  Epigenetic alterations in human parathyroid tumors.

Authors:  Chiara Verdelli; Irene Forno; Valentina Vaira; Sabrina Corbetta
Journal:  Endocrine       Date:  2015-02-27       Impact factor: 3.633

2.  Menin represses tumorigenesis via repressing cell proliferation.

Authors:  Ting Wu; Xianxin Hua
Journal:  Am J Cancer Res       Date:  2011-05-16       Impact factor: 6.166

3.  Expression of p27Kip1 and p18Ink4c in human multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors.

Authors:  E B Conemans; G M Raicu-Ionita; C R C Pieterman; K M A Dreijerink; O M Dekkers; A R Hermus; W W de Herder; M L Drent; A N A van der Horst-Schrivers; B Havekes; P H Bisschop; G J Offerhaus; I H M Borel Rinkes; G D Valk; H Th M Timmers; M R Vriens
Journal:  J Endocrinol Invest       Date:  2017-11-13       Impact factor: 4.256

Review 4.  A Review of the Scaffold Protein Menin and its Role in Hepatobiliary Pathology.

Authors:  Laurent Ehrlich; Chad Hall; Fanyin Meng; Terry Lairmore; Gianfranco Alpini; Shannon Glaser
Journal:  Gene Expr       Date:  2017-04-28

Review 5.  Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1.

Authors:  Koen M A Dreijerink; H T Marc Timmers; Myles Brown
Journal:  Endocr Relat Cancer       Date:  2017-08-15       Impact factor: 5.678

Review 6.  Clinical and molecular genetics of parathyroid neoplasms.

Authors:  John M Sharretts; William F Simonds
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

7.  Raloxifene inhibits menin-dependent estrogen receptor activation in breast cancer cells.

Authors:  H Imachi; X Yu; T Nishiuchi; Y Miyai; H Masugata; K Murao
Journal:  J Endocrinol Invest       Date:  2011-12       Impact factor: 4.256

Review 8.  The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Authors:  Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

9.  Knockdown of menin affects pre-mRNA processing and promoter fidelity at the interferon-gamma inducible IRF1 gene.

Authors:  Lauren B Auriemma; Shaili Shah; Lara M Linden; Melissa A Henriksen
Journal:  Epigenetics Chromatin       Date:  2012-01-12       Impact factor: 4.954

10.  Molecular analysis of MEN1 expression in MCF7, T47D and MDA-MB 468 breast cancer cell lines treated with adriamycin using RT-PCR and immunocytochemistry.

Authors:  E Azizi; A Namazi; S Kaabinejadian; Sh Fouladdel; P Rezaei; M Ramezani
Journal:  Daru       Date:  2010       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.